alexa Efficacy And Safety Of A New Botulinum Toxin A From Strain CBFC26 (NTC, LetibotulinumtoxinA, BOTULAX) For The Treatment Of Post-stroke Upper Limb Spasticity | 70991
ISSN: 2155-9562

Journal of Neurology & Neurophysiology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

13th International Conference on Neurology and Neurosurgery
June 19-21, 2017 Paris, France

Kyung Hee Do,Min Ho Chun, Nam-Jong Paik, Yoon Ghil Park, Shi-Uk Lee, Min-Wook Kim, Don-Kyu Kim and Changjin Lee
Veterans Health Service Medical Center, South Korea
University of Ulsan College of Medicine, South Korea
Seoul National University, South Korea
Seoul National University Bundang Hospital, South Korea
Yonsei University, South Korea
Seoul National University Boramae Medical Center, South Korea
St. Mary's Hospital, Catholic University of Incheon, South Korea
Chung-Ang University, South Korea
Hugel Inc., South Korea
Posters & Accepted Abstracts: J Neurol Neurophysiol
DOI: 10.4172/2155-9562-C1-053
Abstract
Objectives: Botulinum neurotoxin type A (BoNT/A) has been widely used to decrease spasticity and enhance function in stroke patients with upper limb spasticity. In the current study, we investigated a new botulinum neurotoxin type A, termed as letibotulinumtoxinA (Botulax®) and compared its efficacy and safety for post-stroke upper limb spasticity with that of onabotulinumtoxinA (Botox®). Methods: Two kinds of botulinum neurotoxin type A (Botulax® and Botox®) were used. One set of injection were performed and total injected doses were 309.21±62.48U (Botulax group) and 312.64±49.99U (Botox group) (p>0.05). Main measures: Primary outcome was measured using the modified Ashworth scale for wrist flexors at week four and secondary outcome was measured using modified Ashworth scale for wrist flexors, elbow flexors, finger flexors, and thumb flexors as well as global assessment in spasticity, disability assessment scale, and caregiver burden scale at baseline, 4, 8, and 12 weeks. Safety measures including adverse events, vital signs and physical examination, and laboratory tests were also monitored. Results: The mean ages for the Botulax group were 56.81±9.49 and which for the Botox group were 56.93±11.93. In primary outcome, the change in modified Ashworth scale for wrist flexors was -1.45±0.61 in the Botulax group and -1.40±0.57 in the Botox group, and the difference between the two groups was -0.06 (95% CI: -0.23–0.12, p>0.05; p=0.5253). In secondary outcome, both groups also demonstrated significant improvements with respect to modified Ashworth scale, global assessment in spasticity, disability assessment scale, and caregiver burden scale during the study periods (p<0.05), and no significant difference was observed between the two groups (p>0.05). In addition, safety measures showed no significant differences between the two groups (p>0.05). Conclusions: The efficacy and safety of Botulax were comparable with those of Botox in treatment of post-stoke upper limb spasticity.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version